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Abstract
Background and Aims
Surgery is the primary curative option in patients with hepatocellular carcinoma (HCC). Cur-
rent prognostic models for HCC are developed on datasets of primarily patients with ad-
vanced cancer, and may be less relevant to resectable HCC. We developed a
postoperative nomogram, the Singapore Liver Cancer Recurrence (SLICER) Score, to pre-
dict outcomes of HCC patients who have undergone surgical resection.
Methods
Records for 544 consecutive patients undergoing first-line curative surgery for HCC in one
institution from 1992–2007 were reviewed, with 405 local patients selected for analysis.
Freedom from relapse (FFR) was the primary outcome measure. An outcome-blinded
modeling strategy including clustering, data reduction and transformation was used. We
compared the performance of SLICER in estimating FFR with other HCC prognostic models
using concordance-indices and likelihood analysis.
Results
A nomogram predicting FFR was developed, incorporating non-neoplastic liver cirrhosis,
multifocality, preoperative alpha-fetoprotein level, Child-Pugh score, vascular invasion,
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tumor size, surgical margin and symptoms at presentation. Our nomogram outperformed
other HCC prognostic models in predicting FFR by means of log-likelihood ratio statistics
with good calibration demonstrated at 3 and 5 years post-resection and a concordance
index of 0.69. Using decision curve analysis, SLICER also demonstrated superior net bene-
fit at higher threshold probabilities.
Conclusion
The SLICER score enables well-calibrated individualized predictions of relapse following
curative HCC resection, and may represent a novel tool for biomarker research and
individual counseling.
Introduction
Hepatocellular carcinoma is often associated with a poor prognosis and is responsible for a dis-
proportionately high global burden of morbidity and mortality. Its incidence is increasing in
several developed countries, particularly in Asia as a result of a cohort effect related to infection
with hepatitis B and C viruses [1]. To date, surgical resection remains the gold standard treat-
ment in patients with adequate residual liver function, and liver transplant offers the best long
term outcomes for patients with impaired liver function secondary to liver cirrhosis. Ablative
modalities such as radiofrequency ablation or trans-arterial chemo-embolization are frequently
employed for palliative treatment or as a bridge to liver transplant. Despite successful surgical
resection and the use of antiviral drugs in the setting of hepatitis-induced liver cirrhosis, the
risk of relapse is still extremely high with tumor recurrence developing in up to 70% of cases at
5 years [2].
There have been several scoring systems developed for classification and prognostication of
HCC, and these include the American Joint Committee on Cancer staging system 7th edition
(AJCC7), Okuda score, Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Pro-
gram (CLIP), Chinese University Prognostic Index (CUPI) and Japan Integrated Staging Score
(JIS score) [3–9]. These are predominantly derived from patients with metastatic and locally
advanced disease, often with impaired liver function, and have not been validated for use in
prediction of relapse after surgical resection. These scoring systems only serve to classify pa-
tients into various groups with varying outcomes, but do not predict individualized outcomes.
One nomogram based on a smaller dataset in the USA has been proposed to predict disease
free survival, and another has been proposed to predict pulmonary metastases, but to date both
have not been externally validated [10,11].
From a clinical perspective, there is a need for an accurate model for predicting individual-
ized probabilities of HCC recurrence after curative liver resection. This would guide patient
counseling and effective scheduling of clinical surveillance, which is important as early detec-
tion of recurrence could be amenable to further curative surgical resection. The model would
also help in stratifying patients who may benefit from adjuvant treatment, rank potential liver
transplant candidates and serve as a basis for patient selection in clinical trials.
In this study, we have constructed a new postoperative nomogram, the Singapore Liver
Cancer Recurrence (SLICER) Score, to predict the probability of freedom from recurrence in
patients who have undergone curative surgical resection for HCC. We also demonstrate that it
performs better than several major HCC staging systems in use today in predicting probability
of freedom from recurrence.
The Singapore Liver Cancer Recurrence (SLICER) Score
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Patients and Methods
Ethics Statement
Institutional review board approval from the Singapore Health Services was obtained for this
study. All patient records and information was anonymized and de-identified prior to analysis.
Patients
Patients who underwent primary curative resection for HCC were identified through the hos-
pital database and their medical records were reviewed. We limited our dataset to Singaporean
patients who underwent surgery between 1992 and 2007, both to reduce sampling and follow-
up bias, as well as to allow for a sufficient duration of post-resection follow-up data to be ob-
tained. All patients underwent a chest x-ray, and either a liver computed-tomography (CT)
scan or magnetic resonance imaging (MRI) of the liver prior to surgery. Clinical, radiological
and pathological data of these patients were extracted for analysis. The pathological specimens
and slides were reviewed by a pathologist specialized in hepatobiliary pathology and tumor
characteristics, including but not limited to tumor size, encapsulation, presence or absence of
cirrhosis in non-cancerous tissues, resection margin, grade and vascular invasion, were re-
ported. CLIP, CUPI, BCLC, Okuda, Child-Pugh scores and AJCC7 were determined from
available data.
All patients were followed up post-operatively according to standard department practices
at maximum intervals of 6 months. Clinical surveillance consisted of regular clinical evalua-
tions, serum alpha-fetoprotein (AFP) levels and hepatic imaging in the form of ultrasonogra-
phy, CT scan or MRI as deemed appropriate by the surgeon. All imaging done was reviewed
and reported by radiologists specialized in hepatobiliary imaging. A relapse was diagnosed
based on new intra-hepatic or extra-hepatic lesions characteristic of HCC seen on imaging.
Statistical analysis
The clinical endpoint was freedom from recurrence (FFR). This was defined as the time from
date of surgery to date of first relapse detected on imaging, or to the last follow up date for cen-
sored cases. A Kaplan-Meier survival curve was used to estimate FFR and univariable Cox re-
gression was carried out to evaluate the effects of various clinicopathologic variables on FFR.
Clustering of variables was conducted to reduce the number of potential prognostic factors by
evaluating the similarity of these factors [12]. Subsequently, reduced model selection was per-
formed using a backward stepdown by applying the Akaike information criterion [13]. Propor-
tional hazards assumptions were verified systematically for all proposed models. The final
multivariable Cox regression coefficients were used to construct the SLICER nomogram. Inter-
nal validation was performed to evaluate the ability of SLICER nomogram to predict FFR of in-
dividual patients with 200 sets of bootstrap samples as it replicated the development and
validation cycle 200 times and used a full or nearly full version of the dataset for each cycle
[12]. Calibration plots were drawn to explore the performance characteristics of the nomogram
at 3 and 5 years post-resection [12].
Likelihood ratio testing of nested models were performed to compare SLICER to the other
prognostic models including CLIP, CUPI, BCLC, OKUDA, AJCC7 and Memorial Sloan-Ket-
tering Cancer Centre (MSKCC) nomogram on a pairwise basis [12]. An adequacy index was
used to quantify the percentage of the variation explained by a subset of the individual predic-
tors compared with the information contained in the full set of predictors by means of log-like-
lihood [12]. Harrell’s c-index was calculated to evaluate the concordance between predicted
and observed responses of individual subjects separately [12]. Decision curve analyses, plots of
The Singapore Liver Cancer Recurrence (SLICER) Score
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net benefit against threshold probability, were carried out to evaluate these predictive models
by examining the theoretical relation between the threshold probability of developing an event
and the relative value of false-positive and false negative results as described by Vickers et al
[14].
All statistical analyses were done using R 3.0.2 (http://www.R-project.org) and STATA 11
(STATA Corporation, College Station, TX USA), and all tests were two-sided with a signifi-
cance level of 0.05.
Results
Patient characteristics
Between 1992 and 2007, 544 consecutive patients who underwent first-line curative hepatic re-
section for HCC in Singapore General Hospital were recruited. We excluded foreign patients
and patients with missing data (n = 139), leaving 405 patients to form the cohort for our analy-
sis. Their baseline demographic and clinical characteristics are shown in Table 1. The median
age of the cohort was 64 years (range 30–88 years), of which 81.7% were male. The cohort con-
sisted predominantly of patients of Chinese ethnicity (92.6%). 62.5% of our patients had either
a positive hepatitis B surface antigen, chronic hepatitis C infection, or both. Most patients
(89.9%) had biochemical results consistent with Child-Pugh class A status (192 without patho-
logic cirrhosis), early stage disease (60% with AJCC7 stage I). 265 patients (65.4%) were asymp-
tomatic at diagnosis.
Prognosis
The median follow-up was 25.8 months (range 0.03–173.3 months). A total of222 patients re-
lapsed, and there were 171 deaths. The median overall survival of the cohort was 55.9 months
and median FFR was 25.2 months.
Nomogram construction
Univariable analysis showed that Child-Pugh class status, pre-surgery AFP level, non-neoplas-
tic liver cirrhosis, multifocality, vascular invasion, tumor size, margin distance, symptoms,
ECOG (Eastern Cooperative Oncology Group) performance status, histological grade and
AJCC7 stage significantly affected FFR (Table 2). Among these, ECOG status and AJCC7 stage
were excluded from the multivariable analysis as Hoeffding’D statistics showed that ECOG
status and symptoms, vascular invasion and AJCC7 stage were highly correlated (Fig. 1). Final-
ly, 8 of them were found statistically significant in multivariable analysis and selected to con-
struct the nomogram (Table 3, Fig. 2). These include the presence or absence of cirrhosis in the
non-neoplastic liver, tumor multifocality, pre-surgery AFP, Child-Pugh class status, vascular
invasion, tumor size, margin distance and the presence or absence of symptoms at diagnosis.
Bootstrapping was then performed to determine the calibration accuracy for 3-year and 5-year
FFR estimates from the final Cox model. Calibration curves were plotted showing that the
maximum deviation from ideal were 5.6% and 3.9% respectively (Fig. 3).
Comparison of SLICER to alternative staging models as predictor of
FFR
The SLICER score demonstrated superior predictive capabilities relative to the other models
with a hazard ratio of 1.05 (95%CI 1.04–1.06) and concordance index of 0.69 for prediction of
FFR (Table 4). On decision curve analysis [13], compared to other models, our nomogram
showed equivalent net benefit between 0–40% threshold probability, but improved
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Table 1. Baseline demographic and clinical characteristics of 405 patients with resected HCC.
Characteristics Frequency (%)
Age (Median (range)) 64 (30, 88)
Tumor size (cm) (Median (range)) 4.0 (0.4, 20.0)
Margin (mm) (Median (range)) 3 (0, 10)
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performance beyond 40% threshold. This represents superior estimation of decision outcomes
at higher threshold probability levels (Fig. 4). The adequacy index of SLICER was also higher
when compared to the other models individually. In terms of likelihood analysis, its inclusion
in a full model resulted in highly statistically significant improvements when tested with logis-
tic regression analysis against the CLIP (p<0.0001), CUPI (p<0.0001), BCLC (p<0.0001),
OKUDA (p<0.0001), AJCC7 (p<0.0001) and MSKCC (p<0.0001) (Fig. 5).
Discussion
HCC is one of the most common malignancies worldwide, especially in Asia in association
with a high incidence of Hepatitis B and C infection. Surgical resection offers the best prognosis
for long term survival, but little is known about prevention of relapse post-resection and rates
of relapse vary over a wide range in published studies. In our centre, we include patients who
have an ECOG score of 1, who would otherwise be excluded from surgical resection based on
BCLC staging recommendations. This accounts for the high percentage (39.5%) of BCLC stage
C patients included in our study.
Several scoring systems for estimation of prognostic outcomes in HCC have been developed
to risk stratify patients [15–17], and these systems primarily classify patients in to various risk
groups. Nomograms can give each factor a relative weight in prognostication of the outcome,
and permit more refined risk estimation for each individual. However, they are challenging to
create in a very heterogenous disease such as HCC as many factors need to be considered. In
our study, we examined multiple pre-operative and post-operative prognostic factors, and de-
veloped a nomogram to quantify expected individualized recurrence outcomes for HCC pa-
tients treated by first-line surgical resection. We ensured that these variables are common
parameters that are routinely done and easily obtainable for all HCC patients, across all institu-
tions. The SLICER score is meant for use in post-operative patients, and is not meant for pre-
operative counseling of the utility of surgery.
To date, one nomogram has been developed for risk estimation of liver cancer recurrence
and survival post-hepatectomy at the MSKCC [10]. This nomogram was generated from a
small series of 184 patients, and had evident divergence between observed and expected out-
comes during calibration, possibly due to the low numbers involved. This nomogram per-
formed less well in our dataset, possibly due to the different patient profile of HCC in the Asian
population. In our nomogram, patient age was not a defining variable and the presence of
symptoms at diagnosis indicated a higher score. This probably reflects a larger tumor or a later
stage tumor at diagnosis, thus translating to an increased risk of relapse.
Risk factors for postoperative recurrence after resection of HCC are related to tumor, host,
and surgical factors. Pathologic factors indicative of tumor invasiveness such as vascular inva-
sion, multifocality, large tumor size, and advanced pathological TNM (Tumor, Node, Metasta-
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Table 2. Univariable analysis of variables associated with FFR.
Variable No. of patients No. of events Median FFR (months) Hazard Ratio (95% CI) P-value
All 405 222 25.2
Age 405 222 25.2 1.01 (1.00, 1.02) 0.2393
Cirrhosis at non-neoplastic liver 0.0204
No 192 91 33.7 Reference
Yes 211 129 21.8 1.37 (1.05, 1.80)
Satellite nodules or multifocal HCC <0.0001
No 322 163 30.9 Reference
Yes 83 59 10.0 2.34 (1.73, 3.17)
Pre-surgery AFP 0.0001
AFP<10 156 74 33.8 Reference
10AFP<1000 166 97 23.4 1.42 (1.05, 1.92)
1000AFP<10000 31 21 16.9 1.62 (0.99, 2.63)
10000 26 16 7.0 3.28 (1.89, 5.68)
Child-Pugh Score 0.0004
A 364 194 28.6 Reference
B 41 28 13.9 2.02 (1.36, 3.02)
Vascular invasion <0.0001
None 298 151 33.7 Reference
Minor 92 60 11.6 2.01 (1.48, 2.72)
Major 15 11 4.7 3.22 (1.74, 5.96)
Tumor size 397 217 24.6 1.07 (1.04, 1.10) <0.0001
Margin distance 396 216 25.2 0.96 (0.93, 1.00) 0.0412
Symptoms <0.0001
Asymptomatic 265 128 35.2 Reference
Symptomatic 140 94 13.0 2.14 (1.63, 2.80)
ECOG <0.0001
0 240 115 36.4 Reference
1&2&3 165 107 15.5 1.86 (1.43, 2.43)
Grade 0.0349
I 50 25 40.0 Reference
II 170 91 25.0 1.37 (0.87, 2.15)
III 150 84 23.8 1.60 (1.01, 2.52)
IV 14 9 10.4 2.87 (1.32, 6.24)
AJCC7 <0.0001
1 243 112 41.6 Reference
2 103 63 15.6 1.98 (1.45, 2.70)
3a 35 29 5.3 4.03 (2.66, 6.10)
3b 15 11 4.7 3.87 (2.07, 7.20)
4 9 7 11.6 4.34 (2.01, 9.37)
Hep B 0.4490
No 171 92 23.8 Reference
Yes 225 128 25.2 0.90 (0.69, 1.18)
Hep C 0.0748
No 263 132 28.4 Reference
Yes 25 16 15.6 1.60 (0.95, 2.69)
doi:10.1371/journal.pone.0118658.t002
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well as macroscopic portal vein involvement are both major risk factors as metastasis via portal
venous system is an important mechanism for intrahepatic recurrences [19,20]. The effects of
tumor encapsulation and histologic differentiation exert on the risk of recurrence are less con-
clusive. Active inflammatory activity of the non-neoplastic liver has been associated with a
higher proliferative activity and is an independent risk factor for intrahepatic recurrence. Sub-
clinical presentation of HCC is however an independent favorable prognostic factor for dis-
ease-free survival [21]. A few studies had identified perioperative blood transfusion as a risk
factor for HCC recurrence. Most studies found that the extent of resection and whether ana-
tomical or non-anatomical, had no significant influence on the risk of recurrence. The effect
and significance of underlying cirrhosis in the non-neoplastic liver, a wide resection margin to
ensure histologic clearance and administration of neo-adjuvant or adjuvant therapy, on the
risk of recurrence after resection of HCC, has remained controversial [18]. The results shown
in our analysis were consistent with these previous findings.
There has been literature to suggest that early and late recurrence of HCC are thought to be
different—early recurrence thought to be a result of metastasis from the same tumor and late
recurrence thought to be due to de-novo tumors occurring on a background of field change.
The variables we have identified account for both the tumor characteristics (eg. vascular
Fig 1. Important clinical variables identified by clustering. These include pre-surgery serum AFP levels, tumor grade, tumor multifocality, tumor margin
distance, vascular invasion, AJCC7 Staging, the presence or absence of symptoms at diagnosis, ECOG status, Child-Pugh class status, patient’s age at
diagnosis, the presence or absence of cirrhosis in the non-neoplastic liver and tumor size. Hoeffding distance is a ranked based measure of correlation. To
illustrate, this figure shows that there is a stronger correlation between vascular invasion and AJCC staging than between serum AFP and tumour grade.
doi:10.1371/journal.pone.0118658.g001
The Singapore Liver Cancer Recurrence (SLICER) Score
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invasion, multifocality, tumor size) and the possible effect of field change (liver cirrhosis,
Child-Pugh score), thus accounting for both early and late recurrences of HCC.
More than half our study population (55.6%) are known to be Hepatitis B carriers, reflecting
a slightly unique patient profile of HCC patients in Asia. Hepatitis B viral load is known to be
an important predictor of HCC recurrence, with most patients being treated with long-term
anti-viral therapy as it is thought to reduce HCC recurrence. [22] Unfortunately, in the early
part of our study, Hepatitis B viral load was not a routine investigation done for patients and
anti-viral therapy was not readily available, thus this variable was not included in
our nomogram.
In recent years, molecular research has identified various biomarkers as predictive and
prognostic markers for HCC metastatic recurrence and clinical outcomes, including tumor-as-
sociated antigens (such as AFP, MAGEs, GPC3, and CK19), molecular factors associated with
HCC invasion and metastasis (such as E-cadherin, catenins, ICAM-1, laminin-5), and angio-
genesis regulators [23,24]. In particular, elevation of the serum fucosylated fraction of alpha-fe-
toprotein (AFP-L3) level before treatment is a predictor of HCC recurrence, and sustained
elevation of the AFP-L3 level after treatment is an indicator of HCC recurrence [25]. A high
pre-operative level of EpCAM-positive circulating tumour cells and some gene expression sig-
natures have also been found to be a predictor for recurrence [26,27]. However the clinical ap-
plications and availability of these biomarkers is limited and more extensive studies are needed
for validation.
Table 3. Multivariable analysis of variables associated with FFR.
Factor HR (95% CI) p-value
Cirrhosis at non-neoplastic liver
No Reference
Yes 1.75 (1.27, 2.43) 0.0007
Satellite nodules or multifocal HCC
No Reference
Yes 1.97 (1.44, 2.69) <0.0001
Pre-surgery AFP
AFP<10 Reference
10AFP<1000 1.44 (1.06, 1.95) 0.02
1000AFP<10000 1.56 (0.98, 2.47) 0.0594
10000 1.81 (1.02, 3.22) 0.042
Child-Pugh Score
A Reference
B 1.58 (1.04, 2.39) 0.0324
Vascular invasion
None Reference
Minor 1.47 (1.07, 2.04) 0.0189
Major 1.86 (0.6, 3.62) 0.0662
Tumor size 1.04 (1.00, 1.09) 0.0494
Margin distance 0.96 (0.93, 1.00) 0.0573
Symptoms
Asymptomatic Reference
Symptomatic 1.77 (1.31, 2.38) 0.0002
doi:10.1371/journal.pone.0118658.t003
The Singapore Liver Cancer Recurrence (SLICER) Score
PLOS ONE | DOI:10.1371/journal.pone.0118658 April 1, 2015 9 / 17
It is useful to note that molecular studies have shown that 60–70% of recurrences are due to
true metastasis that results from HCC dissemination before resection [28] and occurs mainly
within the first few years after resection [29]. The SLICER score may be predicting a composite
of these outcomes. Potential interventions for high-risk patients identified by the nomogram
may include systemic and hepatic-artery chemotherapy or chemoembolization; however, these
have not been shown to improve overall or disease-free survival after resection of HCC [30].
Early deceased-donor or living-donor liver transplantation is also a consideration. The emer-
gence of targeted therapy such as sorafenib has expanded the scope of therapy in advanced
HCC [31,32]. Consequently, there are several ongoing adjuvant clinical trials evaluating agents
such as sorafenib and gefitinib for HCC patients after potentially curative treatment [11,33],
settings where the SLICER score may be particularly appropriate. While survival remains the
main endpoint to measure effectiveness in phase 3 studies, freedom from recurrence is a useful
and clinically appropriate endpoint in the adjuvant setting after curative treatment for HCC
[34], particularly since repeat resection remains a viable option. A validated nomogram or
model therefore is important to assist in patient selection and future clinical trial design and
biomarker research.
Our results demonstrate that SLICER outperforms other existing established HCC prognos-
tic models in estimation of FFR, and even more importantly, is well calibrated. Certainly it is
true that CLIP, CUPI, BCLC, Okuda scores and AJCC 7th staging systems were developed pri-
marily to predict patient survival rather than relapse. In addition, the data used to develop
Fig 2. SLICER score nomogram. To use the nomogram, locate the first variable. Draw a line straight
upwards to the Points axis to determine the number of points received for the variable. Repeat this process
for other six variables and sum up the points achieved for each variable. The sum of these numbers is located
on the Total Points axis, and a line is drawn downward to the survival axes to determine the likelihood of 3- or
5-year FFR. For example, a patient who has a 3 cm HCCwith multifocality, liver cirrhosis, Child-Pugh A,
minor vascular invasion, resection margin 5 mm, pre-surgery AFP 450ng/mL and he was asymptomatic at
presentation, total points scored is 48. 3- and 5-years FFR is 16 and 8% respectively.
doi:10.1371/journal.pone.0118658.g002
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these models derive mainly from patients with advanced HCC who are not candidates for cura-
tive treatment and who generally have poorer liver function. There is thus a clear need for the
Fig 3. SLICER calibration plots. Plots depict the calibration of SLICER in our dataset in terms of agreement
between predicted and observed 3-year and 5-year FFR. Model performance is shown by the plot, relative to
the 45° gray line which represents perfect prediction. The black line represents observed outcomes and the
blue line represents optimism corrected outcomes generated based on our bootstrap samples.
doi:10.1371/journal.pone.0118658.g003
The Singapore Liver Cancer Recurrence (SLICER) Score
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nomogram we have developed from the largest series to date reported, given the difference in
patient profiles between patients with localized and patients with advanced disease. Even more
importantly, in addition to discriminatory accuracy, our model was able to provide consider-
ably superior estimation of clinical net benefit at higher threshold probability levels, and com-
parable estimation of net benefit at lower threshold probability levels, compared to other
staging systems. It is important to note that the x-axis of the decision curve analysis diagram is
not a direct measurement of model accuracy or performance. It represents a general presenta-
tion of estimating decision outcomes (presented as ‘net benefit’) across a range of different risk
level thresholds, with two extremes ‘all’ or ‘none’ representing two separate extreme assump-
tions (‘all’ will relapse and ‘none’ will relapse). It may be seen from the Fig. 4 (top left image)
for example that the SLICER and CLIP models showed equivalent net benefit between 0%-40%
decision threshold probability, but SLICER showed considerably improved performance over
CLIP beyond 40% decision threshold.
Our study indicated that CUPI was least precise for predicting FFR among the 6 staging
models tested, with a c-index of only 0.54. CLIP and CUPI staging models have been reported
as the most informative regarding survival outcome in advanced HCC [35]. The BCLC classifi-
cations stratify HCC into different stages and defines standard of care for each tumor stage.
BCLC has been widely used as standard classification for trial design and clinical management
of patients with HCC [36]. In our local patient cohort, BCLC does outperform CLIP or CUPI
Table 4. SLICER, CLIP, CUPI, BCLC, OKUDA, AJCC7 and MSKCC models as predictors of FFR.
Model Events/ Patients Hazard Ratio (95% CI) P-value 5-year FFR Concordance Index
SLICER 200/366 1.05 (1.04, 1.06) <0.0001 0.33 0.69
CLIP <0.0001 0.58
0 16/46 Reference 0.48
1 133/236 1.84 (1.09, 3.09) 0.34
2 28/37 3.51 (1.89, 6.50) 0.06
3 18/32 2.24 (1.14, 4.39) 0.31
4–6 5/7 6.64 (2.42, 18.23) NA
CUPI <0.0001 0.54
Low Risk (-7–1) 186/341 Reference 0.33
Intermediate Risk (2–7) 14/17 4.35 (2.50, 7.57) NA
High Risk (8–12) 0/0
BCLC <0.0001 0.60
A 102/211 Reference 0.39
B 13/29 1.37 (0.77, 2.45) 0.39
C 103/160 1.88 (1.43, 2.48) 0.23
D 3/4 4.31 (1.36, 13.69) NA
OKUDA 0.0062 0.54
I 162/307 Reference 0.37
II 57/94 1.53 (1.13, 2.08) 0.17
III 3/4 2.76 (0.88, 8.70) NA
AJCC7 <0.0001 0.65
1 112/243 Reference 0.34
2 63/103 1.97 (1.45, 2.70) 0.17
3 40/50 3.98 (2.76, 5.75) 0.20
4 7/9 4.34 (2.01, 9.37)
MSKCC 116/213 1.01 (1.00, 1.01) 0.0003 0.58
doi:10.1371/journal.pone.0118658.t004
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Fig 4. Decision curve analysis.Decision curve analyses depict the clinical net benefit in pairwise comparisons across the different models. SLICER is
compared against the various prognostic models in terms of 5-year FFR. Dashed lines indicate the net benefit of SLICER in each of the curves across a
range of threshold probabilities. The horizontal solid black line represents the assumptions that no patients will experience the event, and the solid gray line
represents the assumption that all patients will relapse. On decision curve analysis, SLICER showed superior net benefit compared to other models across a
range of threshold probabilities.
doi:10.1371/journal.pone.0118658.g004
The Singapore Liver Cancer Recurrence (SLICER) Score
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with regard to predicting ability for FFR, but is in turn outperformed by SLICER. Likelihood
analysis also showed that inclusion of SLICER in a full model resulted in highly statistically sig-
nificant improvements when tested with logistic regression analysis against the other models.
Fig 5. Likelihood analysis. Likelihood analyses compare the SLICER with each of the various models individually, as well as its inclusion into each model,
in predicting 5-year FFR. SLICER demonstrated higher adequacy index when compared to each model individually, and its inclusion in each model resulted
in highly statistically significant improvements.
doi:10.1371/journal.pone.0118658.g005
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Limitations to our study include its retrospective nature, and that it is based on a single-in-
stitution experience. As our centre sees approximately 70% to 80% of all surgically resectable
patients nation-wide, this may reduce the concern of bias arising from data from a single insti-
tution. External validation at other centres will be required. We did not manage to include
some other variables known to affect recurrence such as iatrogenic intra-operative tumour rup-
ture [37], or histopathological subtypes of HCC. Fibrolamellar HCC occurs in a distinctly dif-
ferent population of patients than common HCC, and is known to have relatively indolent
tumour biology with a better prognosis [38].
Ideally, SLICER should also be paired with a better surveillance model to determine if high-
risk patients as identified by SLICER truly benefit from closer surveillance. To date, there are
no randomized trials of surveillance strategies in post-operative HCC to determine the benefit
of risk-adjusted strategies and SLICER could serve as an appropriate prognostic model for
such trials.
To our knowledge, the SLICER score here is developed on the largest reported series of
post-surgical patients to date. We have developed a model to predict individualized probabili-
ties of relapse following complete resection of localized hepatocellular carcinoma, in a large,
near-national consecutive series of patients, which demonstrates excellent calibration and per-
formance. This provides a foundation for individualized patient counseling and management,
biomarker development, and trial design for adjuvant trials in HCC.
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